Drugs / Ra223
Ra223
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05133440 | Nov 2021 → Apr 2026 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03305224 | Oct 2017 → Oct 2021 | castration-resistant prostate carcinoma, metastatic carcinoma in the bone | Taro Iguchi, MD, PHD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02194842 | Oct 2015 → Feb 2024 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ra223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02194842 ↗ |
| Known as | 223Ra | “Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (223Ra) combined...” PMID 39827019 ↗ Jan 2025 |
| Known as | Radium dichloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05133440 ↗ |
| Known as | radium-223 | “Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (223Ra) combined...” PMID 39827019 ↗ Jan 20251“The Study of Combination Therapy With Radium-223 and Enzalutamide in Osaka City University” NCT03305224 ↗ |
| Route | Intravenous | “Ra-223 (55 kBq/kg i.v.)” NCT03305224 ↗ |